Olema Oncology's novel KAT6 inhibitor OP-3136 demonstrated potent anti-tumor activity in preclinical models of ovarian, prostate, and non-small cell lung cancer, expanding its potential beyond breast cancer.
Olema Oncology is progressing its pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in second/third-line metastatic breast cancer, with top-line data anticipated in 2026.
Olema Oncology has received FDA clearance for its Investigational New Drug (IND) application for OP-3136, a novel KAT6 inhibitor, marking a key regulatory milestone.
Olema Oncology has reported its second quarter 2024 financial results, highlighting promising interim clinical results from the study of palazestrant in combination with ribociclib, and the completion of IND-enabling studies for OP-3136. The company also provided updates on its financial status and upcoming milestones.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.